- Diagnostics
- Monday, 13 Apr 2020
Huami partners with Nanshan Zhong's team to fight COVID-19 coronavirus in a joint laboratory
Huami announced a collaboration with the Chinese National Center for Clinical Research on Lung Disease (NCRCRD) and the Guangdong Nanshan Institute for Medical Innovation, led by Dr. Nanshan Zhong, to establish a joint laboratory to develop smart portable devices. Relying on Huami's intelligent portable technologies and powerful calculation algorithms, the laboratory aims to help monitor and manage COVID-19 cured patients through the NCRCRD big data platform. In addition, the laboratory would jointly contribute to an alert and forecast system for epidemics.
"As a collaboration between medical institutes, research and development institutions and companies, we are excited to use our expertise in intelligent portable technologies to promote applied research and facilitate a real transformation in respiratory health" said Wang Huang , founder and chief executive officer of Huami Technology. Guided by its mission to “connect health to technology”, Huami is determined to create a global health ecosystem including devices, data and services, while being a trusted trusted partner of its users.
Dr Nanshan Zhong, 83, an internationally renowned respiratory specialist and member of the Chinese Academy of Engineering, was a pioneer in the fight against SARS in 2013 and is now the chief expert on COVID-19 prevention with the Chinese National Health Commission. Dr. Nanshan Zhong has been fighting on the front line of the coronavirus epidemic since he reported the first person-to-person transmission of COVID-19 in January.
Since the onset of the coronavirus epidemic, Huami has continued its efforts to "connect health to technology". The company has donated RMB 11.5 million worth of medical supplies and equipment since the start of the epidemic. Huami also developed a smart watch for medical personnel in Wuhan , which has a function to alleviate psychological distress.
Related Industry Updates
CooperRiis Launches New Insurance Driven Intensive Clinical Program
Jul 09, 2020
ArcherDX Receives Approval for Archer®MET Companion Diagnostic for TEPMETKO® (Tepotinib) in Advanced Non-Small Cell Lung Cancer in Japan
Mar 25, 2020
Chinese scientists seeking several potential COVID-19 treatment find 'extremely effective' antibodies
Apr 01, 2020
QuEST Global Enhances its Lung Nodule Detection Solution Using Microsoft Azure IoT Central, Azure IoT Edge and Azure Machine Learning
Jun 12, 2020
Natera Launches Zenith Genomics for Rare Disease in US Healthcare
Mar 13, 2026
Allergy Treatment Progress in Regeneron’s Immunology Pipeline
Feb 11, 2026
ZEUS Scientific Announces New Rapid SARS-CoV-2 Antibody Test
Apr 23, 2020